BioSpace News Archive

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) accepted priority review for its New Drug Application (NDA) for mirabegron for oral suspension and its supplemental New Drug Application (sNDA) for Myrbetriq®

New model for instrument and equipment procurement offers customers subscription-based access to technology, and associated consumables, services and support

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler , President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 C

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper , chairman, president and chief executive officer, will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 , at 3:40 p.m. (EDT) . Among other topics, Mr. Casper will prov

Elevation Oncology , a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today that Shawn M. Leland , PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology, will present at the 39 th Annual J.P. Morgan Healthcare Confere

- AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the Company executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications. The technology is covered by four patent applications already on file with the United States Patent and Trademark Office.

LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced that president and chief executive officer Fred Chereau will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 4:30 pm ET . Mr. Chereau will provide an overview of com

The Phase 2 study will evaluate key physiological measures and is expected to be completed in 3-6 months

BioVentrix, Inc. , a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that heart failure specialist Jerry Estep, MD, of the Cleveland Clinic has been appointed co-principal investigator of the pivotal ALIVE Trial studying LIVE™ Therapy using the Revivent TC™ TransCatheter Ventricular Enhancement System . He join

Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced that it will participate in two upcoming investor conferences.